Buscar
Roivant Sciences Ltd
ROIVAñadir a la lista de seguimiento
38.880USD
+2.260+6.17%
Cierre 11-06 16:00（ET）
28.08BCap. mercado
PérdidaP/E TTM
Fuera de horario 17:02 (ET)38.930USD+0.080+0.21%
Fuera de horario 17:02 (ET)Acerca de Roivant Sciences Ltd Compañía
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Perfil de Roivant Sciences Ltd
Símbolo de cotizaciónROIV
Nombre de la empresaRoivant Sciences Ltd
Fecha de salida a bolsaDec 03, 2020
Director ejecutivoVenker (Eric)
Número de empleados750
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 03
Dirección7Th Floor, 50 Broadway
CiudadLONDON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalSW1H 0DB
Teléfono4412955950
Sitio Webhttp://roivant.com/
Símbolo de cotizaciónROIV
Fecha de salida a bolsaDec 03, 2020
Director ejecutivoVenker (Eric)
Ejecutivos de Roivant Sciences Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.74M
+0.29%
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.74M
+0.29%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
973.50K
-41.09%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
973.50K
-41.09%
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
218.48K
-18.45%
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
218.48K
-18.45%
Dr. Mayukh Sukhatme, M.D.
Dr. Mayukh Sukhatme, M.D.
President, Chief Investment Officer, Director
President, Chief Investment Officer, Director
186.47K
-10.71%
Dr. Mayukh Sukhatme, M.D.
Dr. Mayukh Sukhatme, M.D.
President, Chief Investment Officer, Director
President, Chief Investment Officer, Director
186.47K
-10.71%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
109.97K
+0.74%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
109.97K
+0.74%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.74M
+0.29%
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.74M
+0.29%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
973.50K
-41.09%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
973.50K
-41.09%
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
218.48K
-18.45%
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
218.48K
-18.45%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Roivant Sciences Ltd?
Los cinco principales accionistas de Roivant Sciences Ltd son: Dr. Keith S. Manchester, M.D.
¿Cuántas instituciones poseen acciones de Roivant Sciences Ltd (ROIV)?
A fecha de 2026Q1, 781 instituciones poseen acciones de Roivant Sciences Ltd, con un valor de mercado combinado de aproximadamente 565.52M, lo que representa el 79.01% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -23023750.00.